{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-032950","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.912932+00:00","generated_at":"2026-05-15T09:25:07.863767+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing","bullets":["EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.","Deepening of response across all endpoints over 52 weeks in the full zumilokibart-treated population.","Safety profile consistent with class; common TEAEs: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%).","Part B 16-week induction data expected Q2 2026; Phase 3 initiation in 2H 2026; potential commercial launch in 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-032950","json":"https://secwatch.observer/filing/0001104659-26-032950.json","markdown":"https://secwatch.observer/filing/0001104659-26-032950.md","text":"https://secwatch.observer/filing/0001104659-26-032950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/0001104659-26-032950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/tm269553d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:25:07.863767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}